What is the efficacy of TNF-? antagonists in the treatment of Behçet disease?

Updated: Dec 21, 2020
  • Author: Nicole Davey-Ranasinghe, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

In a multicenter study of the use of TNF-α antagonists (mainly infliximab and adalimumab) for treatment of severe and/or refractory Behçet's disease in 124 patients, clinical response rates with particular organ involvement were as follows [61] :

  • Ocular - 96.3%
  • Mucocutaneous - 88%
  • Joint - 70%
  • GI - 77.8%
  • CNS - 92.3%
  • Cardiovascular - 66.7%

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!